108 results
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
7 Mar 24
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
6:06am
of Study C602, a long-term treatment study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS … assets
Total current assets
Long-term assets
Property and equipment, net
Operating lease right-of-use assets
Intangible assets, net
Other long-term assets
S-3ASR
SLNO
Soleno Therapeutics Inc
2 Jan 24
Automatic shelf registration
4:06pm
and sought continued treatment with DCCR were eligible to receive DCCR in a long-term open-label safety extension study (C602). Top line results from
8-K
EX-1.1
7jkgdklz7ioj
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-1.2
mytml4f1y1yxy9d15t
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
2yl2sn6lt2ykazgeqvn
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
8c0ncyekwi0
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
3eq378
26 Sep 23
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from
7:30am
8-K
EX-99.1
0jnltdek
8 Aug 23
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:25pm
8-K
EX-99.1
wbahwiw o7wvd6viwnv
10 Jul 23
Regulation FD Disclosure
4:06pm
8-K
EX-99.1
x9m6bzhlg6k6vuhxju7d
9 May 23
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
jyq3h
3 May 23
Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
5:26pm